Hikma Pharmaceuticals (LON:HIK – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a note issued to investors on Friday,Digital Look reports. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Get Hikma Pharmaceuticals alerts:Check Out Our Latest Stock Analysis on HIKHikma Pharmaceuticals Trading Up 0.8%Hikma Pharmaceuticals Company ProfileShares of LON:HIK opened at GBX 1,712 on Friday. Featured StoriesReceive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.